Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).
Sumati Gupta(University of Utah), Neeraj Agarwal(Huntsman (United States)), John O Shea(University of Utah), Joshua D. Schiffman(University of Utah), Brian K. Dalley(University of Utah), Lisa M. Pappas(University of Utah), Andrew Butterfield(University of Utah), Sunil Sharma(University of Utah), Alexis Weston(Translational Genomics Research Institute), Daniel J. Albertson(University of Utah), Timothy J. Parnell(University of Utah)
Cited by 2
Related Papers
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
|Journal of Clinical Oncology|2021|530
Comparative oncology: what dogs and other species can teach us about humans with cancer
|Philosophical Transactions of the Royal Society B Biological Sciences|2015|440
Monogenic and polygenic determinants of sarcoma risk: an international genetic study
|The Lancet Oncology|2016|213
Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors
|Science|2018|184
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
|Nature Reviews Clinical Oncology|2021|140